Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

For the first time, UAB researchers have cured mice with diabetes type 1

10.05.2002


A team of researchers from the Universitat Autònoma de Barcelona (UAB) has cured mice with diabetes type 1 for the first time. In the experiment, the diabetic mice completely recovered from the disease after having suffered excesses of glucose in their blood. Although the mice used were transgenic, the researchers are sure that there will soon be a genic therapy based on this discovery that will cure non-transgenic mice with diabetes type 1, and which, within a few years, will also be able to cure people. The study was published in last edition of Journal of Clinical Investigation.



A research team led by Fatima Bosch, professor in the Department of Biochemistry and Molecular Biology at the UAB, has studied the effects of protein IGF-I on mice with diabetes type 1, i.e. the type of diabetes produced by a decrease in the number of beta cells in the pancreas, the ones which produce insulin. In order to study this effect, the researchers used mice that were genetically modified so that the beta cells in their pancreases would produce protein IGF-I, and have compared the development of diabetes type 1 in this type of mice to the evolution of the disease in control mice (without genetic modifications).

The results of the experiments clearly show that in the transgenic mice with the gene that codifies for protein IGF-I activated in beta cells, the induction of experimental diabetes leads to the replication of these cells, their programmed cellular death is counteracted (apoptosis) and the resident mother cells in the conducts of the pancreas are induced to develop insulin-producing beta cells. All these effects lead to the mice completely recovering from the disease, re-establishing absolutely normal levels of glucose in their blood.


The team of UAB scientists chose to experiment with this protein because it has provided excellent results in vitro – it causes the replication of beta cells and counteracts apoptosis – and moreover, mice in which there is destruction of the gene that codifies the IGF-I receptor have very small pancreatic islets (the conglomerates of the beta cells in the pancreas).

This is the first time in which it has been demonstrated that a curative therapy for diabetes is possible, and could imply important advantages over other therapies that are currently being investigated, such as the transplant of islets or beta cells cultivated in vitro. Moreover, in the therapy developed by Doctor Fatima Bosch’s team, the effect of IGF-I does not occur until the animal suffers the destruction of its beta cells. Therefore, non-diabetic transgenic animals are perfectly normal, without any alterations or secondary effects.

The researchers are sure that the next stage of the research programme, the curing of normal (i.e. non-transgenic) mice with diabetes 1 by mean of genic therapy, will probably take place in the near future. Once the scientists have successfully carried out tests with experimental animals, they will be able to consider applying the technique to humans, although this will not be for some time. In order to cure diabetes type 1, viral vectors (innocuous viruses) carrying the gene that codifies for IGF-I will have to be injected into the pancreas.

The research, published in last edition of Journal of Clinical Investigation, has involved the participation of researchers from the Department of Biochemistry and Molecular Biology at the UAB, specifically the Unit from this department based in the Faculty of Veterinary Science, along with members of the Centre for Animal Biotechnology and Genetic Therapy (CBATEG) at the Biocampus research complex of the Universitat Autònoma de Barcelona. The research was financed by the Fondo de Investigación Sanitaria (Health Research Fund), the Plan Nacional de I+D (National R&D Plan) of the Spanish Ministry for Education and Culture, the TV3 Marató Foundation, the Generalitat de Catalunya’s General Research Management and the European Community Training and Mobility Program.

Octavi López Coronado | alphagalileo
Further information:
http://www.uab.es

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>